Key points from article :
Life Bio's gene therapy uses OSK (Yamanaka factors: Oct4, Sox2, and Klf4) to partially reprogram cells, restoring vision in non-human primates.
This approach previously reversed aging and improved vision in mice with glaucoma.
New data shows OSK significantly restored vision and nerve survival in monkeys with simulated NAION (eye stroke).
Key improvements include restored electrical signals, thicker nerve layers, and more healthy nerve bundles.
NAION is a common vision loss in older adults, currently with no effective treatment.
Success in monkeys paves the way for human trials, potentially treating various age-related vision issues.
Life Bio's platform aims to address broader aging-related diseases beyond vision.
“..a major step forward in advancing cellular rejuvenation as a way of treating diseases in the eye and potentially other tissues,” - David Sinclair, Co-Founder of Life Bio.
